Mark Lebwohl

39PUBLICATIONS
89CO-AUTHORS
Infant and child healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Clinical pharmacology and therapeuticsPharmacogenomicsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 20, 2026
Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|Aug 12, 2026
Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.

|Aug 07, 2026
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

|Jul 30, 2026
Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.

|Jun 02, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

Pageof 7

Frequent Collaborators

8 joint publications

Bruce Strober

4 joint publications

Abby A Jacobson

4 joint publications

April W Armstrong

4 joint publications

April W Armstrong